Systematic liquid biopsy identifies novel and heterogeneous mechanisms of acquired resistance in gastrointestinal (GI) cancer patients

Date 28 June 2017
Event ESMO World Congress on Gastrointestinal Cancer 2017
Session ESMO World Congress on Gastrointestinal Cancer 2017
Topics Gastrointestinal Cancers
Pathology/Molecular Biology
Presenter Lipika Goyal
Citation Annals of Oncology (2017) 28 (suppl_3): iii137-iii149. 10.1093/annonc/mdx262
Authors L. Goyal, M. Hazar-Rethinam, G. Siravegna, L. Blaszkowsky, M. Russo, E. Van Seventer, B. Nadres, H. Shahzade, J. Clark, J. Allen, A..J. Iafrate, R. David P., J. Murphy, A. Bardelli, A. Zhu, T. Hong, R. Corcoran
  • /

Abstract

Understanding mechanisms of acquired resistance to targeted therapy can guide strategies to improve clinical outcome. Circulating tumor DNA (ctDNA) provides a non-invasive means to identify concurrent heterogeneous resistance mechanisms emerging during therapy.